Gene: SETD2

29072
HBP231|HIF-1|HIP-1|HSPC069|HYPB|KMT3A|LLS|SET2|p231HBP
SET domain containing 2
protein-coding
3p21.31
Ensembl:ENSG00000181555 MIM:612778 Vega:OTTHUMG00000133514 UniprotKB:Q9BYW2
NG_032091.1
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.805e-1 (AD)  3.570e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs9828473chr3:47118198 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KMT2E0.924
BAZ1B0.919
ARHGAP210.91
BPTF0.902
INO800.901
CDC42BPA0.897
GOLGB10.895
SF3B10.888
PRRC2C0.887
TRIP120.887

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.642
OR4F5-0.617
OR4F16-0.288
GSDMC-0.216
KRTAP19-1-0.203
LCE3B-0.202
PLA2G5-0.202
PON3-0.2
SLC22A6-0.2
IAPP-0.191

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SETD2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SETD2 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of SETD2 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of SETD2 mRNA19770486
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of SETD2 mRNA24449571
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of SETD2 mRNA"20382639
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SETD2 mRNA"19150397
D001599BerberineBerberine results in increased expression of SETD2 mRNA27311644
C006780bisphenol Abisphenol A affects the expression of SETD2 mRNA21786754
C006780bisphenol Abisphenol A results in increased methylation of SETD2 gene28505145
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SETD2 mRNA28628672
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of SETD2 mRNA15336504
D002104CadmiumCadmium results in decreased expression of SETD2 mRNA23369406
C030973cupric oxidecupric oxide results in decreased phosphorylation of SETD2 protein25470785
D003676DeferoxamineDeferoxamine affects the expression of SETD2 mRNA23483119
D003676DeferoxamineDeferoxamine results in increased expression of SETD2 mRNA23483119
D013759DronabinolDronabinol results in increased expression of SETD2 mRNA16616335
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SETD2 mRNA28628672
D000431EthanolEthanol results in decreased expression of SETD2 mRNA29018328
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of SETD2 mRNA17555576
D005557FormaldehydeFormaldehyde results in decreased expression of SETD2 mRNA20655997
C001277geldanamycingeldanamycin results in increased expression of SETD2 mRNA26705709
D019833GenisteinGenistein results in increased expression of SETD2 protein24552547
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of SETD2 mRNA18951874
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SETD2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SETD2 mRNA28628672
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of SETD2 mRNA22802445
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of SETD2 mRNA26272509
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of SETD2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of SETD2 mRNA"25554681
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of SETD2 mRNA25729387
D011794QuercetinQuercetin results in decreased expression of SETD2 protein19207037
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SETD2 mRNA21570461
D013806TheophyllineTheophylline results in decreased expression of SETD2 mRNA18951874
D013849ThimerosalThimerosal results in decreased expression of SETD2 mRNA27188386
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of SETD2 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of SETD2 mRNA25729387
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SETD2 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of SETD2 mRNA26272509
D014635Valproic AcidValproic Acid results in decreased expression of SETD2 mRNA28001369
D014810Vitamin EVitamin E results in decreased expression of SETD2 mRNA19244175
C111237vorinostatvorinostat results in decreased expression of SETD2 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI17500595  19141475  21988832  28753426  
GO:0016279protein-lysine N-methyltransferase activity-IDA28753426  
GO:0018024histone-lysine N-methyltransferase activity-IDA23043551  
GO:0018024histone-lysine N-methyltransferase activity-IMP23622243  
GO:0018024histone-lysine N-methyltransferase activity-TAS-  
GO:0043014alpha-tubulin binding-IDA27518565  
GO:0046872metal ion binding-IEA-  
GO:0046975histone methyltransferase activity (H3-K36 specific)-IDA24843002  26002201  27474439  28753426  
GO ID GO Term Qualifier Evidence PubMed
GO:0001525angiogenesis-IEA-  
GO:0001763morphogenesis of a branching structure-IEA-  
GO:0001843neural tube closure-IEA-  
GO:0006298mismatch repair-IMP23622243  
GO:0006355regulation of transcription, DNA-templated-IEA-  
GO:0006368transcription elongation from RNA polymerase II promoter-IMP23325844  
GO:0010569regulation of double-strand break repair via homologous recombination-IDA24843002  
GO:0010793regulation of mRNA export from nucleus-IMP19141475  
GO:0018023peptidyl-lysine trimethylation-IDA27518565  
GO:0018026peptidyl-lysine monomethylation-IDA28753426  
GO:0030900forebrain development-IEA-  
GO:0032465regulation of cytokinesis-IDA27518565  
GO:0032727positive regulation of interferon-alpha production-IDA28753426  
GO:0034340response to type I interferon-IDA28753426  
GO:0034728nucleosome organization-IMP23325844  
GO:0035441cell migration involved in vasculogenesis-IEA-  
GO:0035987endodermal cell differentiation-ISS-  
GO:0048332mesoderm morphogenesis-IEA-  
GO:0048701embryonic cranial skeleton morphogenesis-IEA-  
GO:0048863stem cell differentiation-ISS-  
GO:0048864stem cell development-IEA-  
GO:0051607defense response to virus-IDA28753426  
GO:0060039pericardium development-IEA-  
GO:0060669embryonic placenta morphogenesis-IEA-  
GO:0060977coronary vasculature morphogenesis-IEA-  
GO:0097198histone H3-K36 trimethylation-IDA23043551  24843002  26002201  27474439  28753426  
GO:0097198histone H3-K36 trimethylation-IMP19141475  23325844  23622243  
GO:0097676histone H3-K36 dimethylation-IDA26002201  
GO:1902850microtubule cytoskeleton organization involved in mitosis-IDA27518565  
GO:1905634regulation of protein localization to chromatin-IDA24843002  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-ISS-  
GO:0005654nucleoplasm-TAS-  
GO:0005694chromosome-ISS-  
KEGG ID KEGG Term
hsa00310Lysine degradation
Reactome ID Reactome Term Evidence
R-HSA-3214841PKMTs methylate histone lysinesTAS
R-HSA-3247509Chromatin modifying enzymesTAS
R-HSA-4839726Chromatin organizationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal